UK

The Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory authority responsible for overseeing the safety, quality, and efficacy of medicines, medical devices, diagnostics, and digital health technologies in the United Kingdom. Since the UK's departure from the European Union, the MHRA operates independently from the European Medicines Agency (EMA) and the EU CE marking framework, granting its own UK Conformity Assessed (UKCA) mark for medical devices and conducting sovereign medicines assessments under the Human Medicines Regulations 2012 and the Medical Devices Regulations 2002 (as amended). Pharmaceutical approvals may proceed via several routes, including the national standard route, the international recognition procedure (IRP), and an expedited access pathway for innovative or critical medicines. Medical devices and diagnostics must be registered on the MHRA device registration database and, where required, undergo conformity assessment through a UK-approved body.

For pharmaceutical submissions, the MHRA accepts dossiers in Common Technical Document (CTD) format, aligned with ICH guidelines, making submissions broadly compatible with other major regulatory jurisdictions. A UK-based Responsible Person or local legal representative is required for marketing authorisation holders not established in the UK. Northern Ireland retains a dual regulatory position, where EU CE marking remains valid under the Windsor Framework, creating a distinct compliance consideration for manufacturers. Notable recent reforms include the MHRA's Innovative Licensing and Access Pathway (ILAP), the roll-out of the new UK MDR framework replacing the EU MDR transitional arrangements, and growing regulatory provisions for software as a medical device (SaMD) and AI-driven health technologies. The MHRA has also expanded its international recognition procedure to fast-track approvals for products already authorised by trusted reference agencies such as the FDA, EMA, Health Canada, and the TGA.

Public procurement of health products in the UK is structured primarily through NHS England, which commissions the majority of healthcare services and products for England, while NHS Scotland, NHS Wales, and the Health and Social Care (HSC) system in Northern Ireland operate as devolved purchasing bodies with distinct procurement policies and frameworks. Centralised procurement is coordinated largely through NHS Supply Chain, a government-mandated intermediary that manages framework agreements, category towers, and consolidated purchasing for medical devices, diagnostics, consumables, and capital equipment on behalf of NHS trusts. Pharmaceuticals are subject to separate national arrangements, including the Pharmaceutical Price Regulation Scheme (PPRS) and its successor the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), which governs pricing negotiations between industry and the Department of Health and Social Care (DHSC). The National Institute for Health and Care Excellence (NICE) plays a central role in health technology assessment (HTA), issuing guidance on clinical and cost effectiveness that directly influences formulary listing, commissioning decisions, and reimbursement for medicines, devices, and diagnostics across the NHS.

The private healthcare sector in the UK, served by providers such as Bupa, Nuffield Health, and HCA Healthcare, procures health products independently through direct supplier agreements and group purchasing organisations, and is not subject to NICE guidance or NHS pricing frameworks. The UK does not rely on multilateral donor channels such as UNICEF Supply Division, the Global Fund, or USAID for domestic health product procurement, as these mechanisms are associated with lower- and middle-income country markets. However, the UK Government, through the Foreign, Commonwealth and Development Office (FCDO) and UK Aid programmes, is an active donor and co-funder in global health procurement initiatives, including Gavi, the Vaccine Alliance, and the Global Fund. Domestically, there are no formal local manufacturing preference policies mandating domestic sourcing for NHS procurement, though the DHSC and NHS England have increasingly emphasised supply chain resilience and domestic manufacturing capacity as strategic priorities, particularly following disruptions experienced during the COVID-19 pandemic, with targeted investment in onshore vaccine and medicines manufacturing through bodies such as the Vaccines Manufacturing and Innovation Centre (VMIC).